Skip to main content

Today's Cannabis Economic News (2026-04-29 JST)

News SummaryThis article summarizes the key points by organizing the updates from multiple sources.
Published 2026.04.29Updated 2026.04.29 05:41
Today's Cannabis Economic News (2026-04-29 JST)

Medical marijuana in the United StatesFederal Schedule IIIThe impact of this transition is spreading in various areas, with simultaneous restructuring of state regulations, tax and compliance adjustments, and scrutiny of capital markets.
In Europe, the rapid expansion of demand for medical flowers destined for Germany has led to continued seismic shifts in the supply chain, including in the British Channel Islands.JerseyIts presence is growing stronger.
On the other hand,vapeIssues surrounding data-driven research and validation, such as risk reduction and the validity of diagnostic tools, are crucial to the credibility of businesses.

Regulatory and policy updates

  • The scope of federal rescheduling and the reactions of states: U.S. Department of JusticeActing Attorney General Todd BranchBut,Under state medical licenseor sending us a message onFDA Approved ProductsCannabis products that fall under this category will be moved to Schedule III. In Nebraska, many state and federal lawmakers are maintaining a cautious stance, while the Omaha tribe...John CartierHe stated, "The federal government's excuse for saying it has 'no medical use' is gone."(Marijuana Moment)
  • Tax Guidance: The U.S. Treasury Department and IRS have received a final order to reschedule.Federal tax treatmentThe process for developing guidance on this matter has been announced. The target is the change to "Schedule III for marijuana products approved by the FDA or under a state medical license."Unapproved and unincorporated bulk products and crops remain under Schedule ITo summarize.(Cannabis Law Report)
  • DEA-related developments: Industry newslettersStarting this week, certain federal protection applications can be submitted to the DEA.The government posted the topic, and its spokesperson explained that "the rescheduling has overwhelming support from the public."(Marijuana Moment)
  • Progress and stagnation in state policies:
    • Virginia: Start of retailJuly 1, 2027The assembly rejected the governor's proposal to postpone the bill's approval. The decision on whether to pass or fail the bill will once again rest with the governor.(Marijuana Moment)
    • Maryland: State and municipal employmentFirefighter/Emergency medical personnelabout,Medical marijuana use while off dutyDisadvantageous treatment based on the above reasonAfter January 10prohibit.(Marijuana Moment)
    • North Carolina: Following the rescheduling, Senate ruling party leaderReconsidering the legalization of medical marijuanasuggests.(Marijuana Moment)
  • International perspective: The official recognition of "medical usefulness" in the United States isApproaching the European policy axisAt an industry conference in London, the rescheduling was seen as a signal of a "structural transformation that goes beyond just taxes and research."(Business of Cannabis)
Key policy and regulatory topicsKey pointsSource
Federal reschedulingState medical license/FDA approved products remain at Schedule III, while bulk products remain at Schedule I.Cannabis Law Report, Marijuana Moment
Tax guidanceThe Treasury Department and the IRS have published the process for issuing guidance on how federal taxes are treated.Cannabis Law Report
DEA relatedThis week, the movement to file for federal protection was a hot topic in the newsletter.Marijuana Moment
state trendsA stalemate has been reached over the timing of the start of VA retail sales; MD is protecting the rights of fire/ambulance workers, while NC is reconsidering legislation.Marijuana Moment etc.

Company/market trends

  • Stock Market: Today, mainly US MSOs (Multistate Operators)Rally.MSOS The+ 10.04 %comes$5.15,Green Thumb (GTBIF) The+ 13.85 %,Cresco Lab (CRLBF) The+ 19.00 %comes$1.19The BoC Cannabis Index is+ 2.74 %.(Business of Cannabis)
  • M&A perspective:ReschedulingThe focus is now on reviewing the evaluation of the medical sector, including Tillray, Aurora, Organigram, and Curareef.European Healthcare InfrastructureThe possibility of a re-evaluation. In Europe, it is alreadyM&A waveAnalysis suggests that this is ongoing.(Business of Cannabis)
  • European supply chain:Germany's medical cannabis imports are projected to exceed 200 tons for the first time in 2025.And it's about three times the 2024 figure. Q4 is compared to the previous quarter.Approximately 4.5% decreaseAnd while taking a break,Jersey is ahead of ColombiaThey have a strong presence in supplying flowers. Approximately [percentage missing] of the island's production.90 %This is handled by a single-cultivation company.(Business of Cannabis)
  • The "lack of evidence" problem in the beverage category:Failure to submit verification dataIndustry commentators argue that this increases the risk of regulatory backlash. If you want "evidence-based regulation,"Independent verificationThey pointed out that the product should be released there.(Marijuana Moment)
  • On-site supply and intermediary signals: In the processing and distribution community,Δ8 (D8)comesCompliance inspectedBulk supply,THCA FlowerPartner search, etc.Supply securing and raw material procurementThe trend continues.(Future4200: D8) / (Future4200: THCA)
  • Compliance and reputation:Contradictory messages from state to stateThis is not a brand issue.Operational and regulatory risksThis expert column states that banks and authorities cross-reference publicly available information to assess consistency.(Cannabis Industry Journal)
Today's market indicatorsNumerical valueSource
AdvisorShares Pure US Cannabis ETF (MSOS)+10.04% ($5.15)Business of Cannabis
Green Thumb Industries (GTBIF)+ 13.85 %Business of Cannabis
Cresco Labs (CRLBF)+19.00% ($1.19)Business of Cannabis
BoC Cannabis Index+2.74% (weighted average of 39 stocks, etc.)Business of Cannabis

Research/Technology/Quality

  • vapeand harmful ingredients: Device manufacturerPAXIn a self-published study, compared to joint smoking...Harmful substances are up to 99% less.(reported)16 species of(Comparing harmful/potentially harmful components). Heating temperature and avoidance of combustion are factors. However,Manufacturer-led researchPlease note this point.(leafie)
  • Usage impairment assessment tool:Cannabis use disorderScreening/diagnostic tools (CAST, CUDIT-R, SDS, ASSIST, etc.)ValidityA systematic review and meta-analysis summarizing these findings have been published, organizing the characteristics of psychometrics in diverse groups and situations.(PubMed)
  • GMP and Consistency: In the EU Healthcare MarketcGMP compliantThe importance of this is being discussed, from cultivation to packaging.Microbial contamination controlImported biomassLot-to-lot consistencyis the key.(Cannabis Industry Journal)
  • New materials for receptor research:CB1 receptorHaving a recognizable motifSelenoCannsWe report on a rapid synthesis platform.Na2SeSO3Using aqueous conditions, a variety of organic selenium compounds were synthesized all at once.Structural–functional analysisThis suggests potential applications in fluorescent probes and covalent drug conjugates.(PubMed)
European market and supply chainQuantitative PointsSource
Importation of medical cannabis into Germany (2025)First time exceeding 200 tons, nearly three times the 2024 figure.Business of Cannabis
Q4 import trendsApproximately 4.5% decrease compared to the previous periodBusiness of Cannabis
Jersey Island → Germany supplySurpassing Colombia in flower supply, a single company handles approximately 90% of the island's production.Business of Cannabis

Voices of experts and industry professionals

"Nebraska officials can still oppose medical marijuana,The federal government says it has "no medical use.""We can no longer hide behind that claim." — John Cartier (Attorney General of the Omaha Tribe)
Source:Marijuana Moment
"The industryEvidence-basedWhile demanding detailed regulations,Independent verification"We won't release products to them. They're incompatible." — Leah Collos (23rd State)
Source:Marijuana Moment
Academic perspective (statistics):
"The effects of policies and products are,Control and measurement indicatorsThis needs to be backed up with clear data. We must be mindful of sample bias and sponsor influence.reproducibilityLet's make our decision based on that.

A simple explanation of terms

Schedule III:
The US federal drug classification. It is recognized as having medical value and is regulated, but less strictly than Schedule I drugs. In this final order,Under a state medical license,FDA Approved ProductsThe scope has shifted,Unapproved bulk products are not included.It is organized as follows:
Source:Cannabis Law Report
cGMP (Good Manufacturing Practices for Pharmaceuticals):
Manufacturing and management standards to ensure consistent quality and safety.Import/Export・Lot ManagementWhen doing so, microbial risk reduction and process validation are required.
Source:Cannabis Industry Journal

Cultural and historical topics (connections to economics)

  • Agricultural History of the Chinese Neolithic Period: New Research Places Hemp on the Same Level as the "Five Grains"基幹作物Positioned as such,Food and FiberIt was reported to be deeply integrated into daily life in ancient times.versatilityThis offers insights that are relevant to the diversification of modern industrial applications (medical, textiles, functional components).(Marijuana Moment)

Today's highlights (3 points)

  1. The fate of taxesThe Treasury Department and the IRS have guidance on moving to Schedule III.Effective tax rateThe focus will now be on how this will affect things like expense deductions.Source
  2. European supply chain restructuring: The rapid expansion of demand in Germany,Jersey Island → GermanyThe rise of [this] will impact import sources and price formation. The persistence of the Q4 slowdown also needs to be monitored.Source
  3. Market sentimentThe MSO-led rally isHoping for a reschedulingwithM&A speculationThis is the background. Within the sectorChinese(Note that US MSOs are rising, while some Canadian and consumer goods companies are falling.)Source / Source

Collection List

Share this article

    RANKING

    Choose from popular products

    Top of page